Agonistic Antibodies Reveal the Function of GPR56 in Human Glioma U87-MG Cells

Access this Article

Author(s)

    • Mizuno Norikazu
    • Department of Biomedical Science, Graduate School of Biological Sciences, Nara Institute of Science and Technolog|Faculty of Pharmaceutical Science, Aomori University
    • Tago Kenji
    • Department of Biomedical Science, Graduate School of Biological Sciences, Nara Institute of Science and Technolog|Department of Biochemistry, School of Medicine, Jichi Medical University
    • Itoh Hiroshi
    • Department of Biomedical Science, Graduate School of Biological Sciences, Nara Institute of Science and Technolog

Abstract

GPR56 is a member of the adhesion G protein-coupled receptor (GPCR) and is highly expressed in parts of tumor cells. The involvement of GPR56 in tumorigenesis has been reported. We generated agonistic monoclonal antibodies against human GPR56 and analyzed the action and signaling pathway of GPR56. The antibodies inhibited cell migration through the Gq and Rho pathway in human glioma U87-MG cells. Co-immunoprecipitation analysis indicated that the interaction between the GPR56 extracellular domain and transmembrane domain was potentiated by agonistic antibodies. These results demonstrated that functional antibodies are invaluable tools for GPCR research and should open a new avenue for therapeutic treatment of tumors.

Journal

  • Biological and Pharmaceutical Bulletin

    Biological and Pharmaceutical Bulletin 38(4), 594-600, 2015

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130005062265
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • ISSN
    0918-6158
  • NDL Article ID
    026283605
  • NDL Call No.
    Z53-V41
  • Data Source
    NDL  J-STAGE 
Page Top